We have located links that may give you full text access.
The Effects of Medication Therapy Management on Medication Utilization among Medicare Beneficiaries with HIV/AIDS.
Journal of the American Pharmacists Association : JAPhA 2024 January 4
BACKGROUND: Medicare Part D plans are required to provide Medication therapy management (MTM) programs to eligible beneficiaries to optimize medication utilization. MTM programs' effects on medication utilization among older persons living with HIV/AIDS (PLWHs) remain unclear.
OBJECTIVE: This study examined the effects of the Medicare MTM programs on medication utilization among PLWHs.
METHODS: This study analyzed 2017 Medicare databases linked to the Area Health Resources Files. Recipients and non-recipients of the MTM services were compared on their medication utilization: adherence to antiretroviral medications, drug-drug interactions, and concurrent use of opioids and benzodiazepines. The intervention group comprised recipients of the medication therapy management services, and the control group was non-recipients meeting the eligibility criteria. A propensity score with a ratio of 1:2 between the intervention and control groups was used to identify study groups with balanced characteristics. A logistic regression was used to control for patient/community characteristics.
RESULTS: After matching, the intervention and comparison groups comprised 3,298 and 6,596 beneficiaries for the antiretroviral adherence measure, 809 and 1,618 for the drug-drug interactions measure, and 691 and 1,382 for the concurrent use of opioids and benzodiazepines measure. The intervention was associated with higher odds of adherence to antiretroviral medications (adjusted odds ratio = 1.15, 95% Confidence Interval = 1.04 - 1.26), and no concurrent use of opioids and benzodiazepines (adjusted odds ratio = 1.255, 95% Confidence Interval = 1.005 - 1.568). The study groups did not differ on no drug-drug interactions (adjusted odds ratio = 0.95, 95% Confidence Interval = 0.74 - 1.20).
CONCLUSIONS: Medicare MTM programs effectively improved medication utilization among people living with HIV/AIDS. Future studies should explore the long-term effects of the program.
OBJECTIVE: This study examined the effects of the Medicare MTM programs on medication utilization among PLWHs.
METHODS: This study analyzed 2017 Medicare databases linked to the Area Health Resources Files. Recipients and non-recipients of the MTM services were compared on their medication utilization: adherence to antiretroviral medications, drug-drug interactions, and concurrent use of opioids and benzodiazepines. The intervention group comprised recipients of the medication therapy management services, and the control group was non-recipients meeting the eligibility criteria. A propensity score with a ratio of 1:2 between the intervention and control groups was used to identify study groups with balanced characteristics. A logistic regression was used to control for patient/community characteristics.
RESULTS: After matching, the intervention and comparison groups comprised 3,298 and 6,596 beneficiaries for the antiretroviral adherence measure, 809 and 1,618 for the drug-drug interactions measure, and 691 and 1,382 for the concurrent use of opioids and benzodiazepines measure. The intervention was associated with higher odds of adherence to antiretroviral medications (adjusted odds ratio = 1.15, 95% Confidence Interval = 1.04 - 1.26), and no concurrent use of opioids and benzodiazepines (adjusted odds ratio = 1.255, 95% Confidence Interval = 1.005 - 1.568). The study groups did not differ on no drug-drug interactions (adjusted odds ratio = 0.95, 95% Confidence Interval = 0.74 - 1.20).
CONCLUSIONS: Medicare MTM programs effectively improved medication utilization among people living with HIV/AIDS. Future studies should explore the long-term effects of the program.
Full text links
Related Resources
Trending Papers
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
SGLT2 Inhibitors in Kidney Diseases-A Narrative Review.International Journal of Molecular Sciences 2024 May 2
Use of Intravenous Albumin: A Guideline from the International Collaboration for Transfusion Medicine Guidelines.Chest 2024 March 5
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app